TBIO 2.60 Transgenomic Inc $TBIO Hit a 52 week low of 2.39 Currently at 2.60 -0.02 -0.76% With a day low of 2.39 and a total volume of 34,200.
TBIO Transgenomic Inc Recent Headline News
Transgenomic Announces Executive Changes
Business Wire - Wed Nov 05, 7:30AM CST
Transgenomic, Inc. (NASDAQ:TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical and research services, today announced certain executive management changes. Mark Colonnese, the Chief Financial Officer and Executive Vice President of Transgenomic, resigned from the Company effective October 30, 2014. Paul Kinnon, Transgenomic's President and Chief Executive Officer, will assume the role of Interim Chief Financial Officer. Additionally, Leon Richards, Transgenomic's Corporate Controller, will take on additional responsibilities as Chief Accounting Officer for Transgenomic.
TBIO: 2.60 (-0.02)
Transgenomic Reports Third Quarter 2014 Financial Results
Business Wire - Thu Oct 30, 6:02AM CDT
Transgenomic, Inc. (NASDAQ:TBIO) today reported financial results for the third quarter ended September 30, 2014, and provided a business update.
TBIO: 2.60 (-0.02)
Transgenomic and University of Melbourne Collaborate to Further Validate Ability of Multiplexed ICE COLD-PCR(TM) to Enable Personalized Cancer Treatment
Business Wire - Thu Oct 30, 6:00AM CDT
--MX-ICP Technology Enables Ultra-Sensitive Detection and Monitoring of Multiple Known and Unknown Cancer Mutations in a Single Assay Using Tumor Biopsy or Blood
TBIO: 2.60 (-0.02)
Transgenomic to Hold Third Quarter Financial Results Conference Call on October 30, 2014 at 8:30AM ET
Business Wire - Thu Oct 23, 6:00AM CDT
Transgenomic, Inc. (NASDAQ: TBIO), today announced that the company will hold its Third Quarter 2014 Financial Results and Business Update Conference Call on Thursday, October 30, 2014 at 8:30 AM ET.
TBIO: 2.60 (-0.02)
Transgenomic Announces $2.375 Million Private Placement Financing
Business Wire - Wed Oct 22, 3:06PM CDT
Transgenomic, Inc. (NASDAQ: TBIO) announced today that it has raised gross proceeds of approximately $2.375 million in a private placement financing with a syndicate of new and existing institutional and other accredited investors. The Company's common shares were priced at $3.25 per share, which represents a premium to the closing stock price on October 21, 2014. For each share of common stock purchased, investors also received a warrant to purchase 0.5 shares of the Company's common stock at an exercise price of $4.00 per share. The warrants have a term of exercise equal to five years from the first date of exercise, which is six months following the closing date. In the aggregate, the Company issued approximately 0.73 million shares of common stock and 0.37 million warrants.
TBIO: 2.60 (-0.02)
Transgenomic to Present at BTIG Emerging Technologies in Healthcare Diagnostics Conference
Business Wire - Wed Sep 24, 6:00AM CDT
Transgenomic, Inc. (NASDAQ:TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical and research services, today announced that senior management will participate in the BTIG Emerging Technologies in Healthcare Diagnostics conference. Transgenomic's Executive Vice President and Chief Financial Officer Mark Colonnese will discuss Personalized Medicine in the CLIA Lab on Monday, September 29, 2014 at 4:10 pm ET.
TBIO: 2.60 (-0.02)
Transgenomic to Present at Fifth Annual Craig-Hallum Alpha Select Conference
Business Wire - Mon Sep 15, 10:00AM CDT
Transgenomic, Inc. (NASDAQ: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical and research services, today announced that senior management will give a corporate presentation at the Fifth Annual Craig-Hallum Alpha Select Conference being held at the Convene Conference Center in New York City. Transgenomic's Executive Vice President and Chief Financial Officer Mark Colonnese will present on Thursday, September 18,2014 at 8:40 am ET.
TBIO: 2.60 (-0.02)
Transgenomic to Present at Rodman & Renshaw 16th Annual Global Investment Conference
Business Wire - Fri Sep 05, 6:00AM CDT
Transgenomic, Inc. (NASDAQ:TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical and research services, today announced that senior management will give a corporate presentation at the Rodman & Renshaw 16th Annual Global Investment Conference being held at the New York Palace Hotel in New York City. Transgenomic will present on Wednesday, September 10, 2014 at 11:15 am ET. Transgenomic Chief Executive Officer Paul Kinnon and Chief Financial Officer Mark Colonnese will participate.
TBIO: 2.60 (-0.02)
Transgenomic Reports Second Quarter 2014 Financial Results
Business Wire - Wed Aug 06, 3:06PM CDT
Transgenomic, Inc. (NASDAQ:TBIO) today reported financial results for the second quarter ended June 30, 2014, and provided a business update.
TBIO: 2.60 (-0.02)
Reminder: Transgenomic to Hold Second Quarter Financial Results Conference Call Today
Business Wire - Wed Aug 06, 6:00AM CDT
Transgenomic, Inc. (NASDAQ: TBIO) today announced the following Webcast:
TBIO: 2.60 (-0.02)
Transgenomic Announces Issuance of New European Patent Covering COLD-PCR Technologies
Business Wire - Thu Jul 31, 6:00AM CDT
Transgenomic, Inc. (NASDAQ: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical and research services, today announced that the European Patent Office has issued a new patent, European Patent No. 21833798, covering one of its COLD-PCR family of DNA amplification technologies. The patent covers Full COLD-PCR, a foundation for the company's highly sensitive ICE COLD-PCR technology. The COLD-PCR technology is owned by the Dana-Farber Cancer Institute, Boston USA, and exclusively licensed to Transgenomic.
TBIO: 2.60 (-0.02)
Transgenomic to Hold Second Quarter Financial Results Conference Call on August 6, 2014
Business Wire - Wed Jul 30, 3:30PM CDT
Transgenomic, Inc. (NASDAQ:TBIO) today announced the following Webcast:
TBIO: 2.60 (-0.02)
Transgenomic Sells Rights to SURVEYOR Mutation Detection Technology and Assets to Integrated DNA Technologies, Inc.
Business Wire - Wed Jul 02, 6:00AM CDT
Transgenomic, Inc. (NASDAQ:TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical and research services, today announced that it has entered into an agreement to sell to Integrated DNA Technologies, Inc. (IDT) the rights to Transgenomic's SURVEYOR Nuclease technology and assets for a minimum of $4.25 million. SURVEYOR Mutation Detection Kits provide researchers with a simple, robust and versatile method to detect mutations and polymorphisms in DNA from a variety of organisms.
TBIO: 2.60 (-0.02)
Dr. Michael A. Luther Joins Transgenomic's Board of Directors
Business Wire - Wed Mar 19, 6:00AM CDT
Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, today announced the appointment of Michael A. Luther, Ph.D., to its Board of Directors. Dr. Luther will also become a member of the Board's audit committee. His appointment became effective March 13, 2014.
TBIO: 2.60 (-0.02)
Transgenomic Reports Fourth Quarter and Fiscal Year 2013 Financial Results
Business Wire - Wed Mar 12, 3:10PM CDT
Transgenomic, Inc. (OTC/BB: TBIO) today reported financial results for the fourth quarter and year ended December 31, 2013, and provided a business update.
TBIO: 2.60 (-0.02)
Reminder: Transgenomic to Hold Fourth Quarter Financial Results Conference Call Today
Business Wire - Wed Mar 12, 7:44AM CDT
Transgenomic, Inc. (OTC/BB: TBIO) today announced the following Webcast:
TBIO: 2.60 (-0.02)
Transgenomic to Hold Fourth Quarter Financial Results Conference Call on March 12, 2014
Business Wire - Thu Mar 06, 10:51AM CST
Transgenomic, Inc. (OTC/BB: TBIO) today announced the following Webcast:
TBIO: 2.60 (-0.02)
Transgenomic Announces $7 Million Convertible Preferred Stock Financing
Business Wire - Thu Mar 06, 6:30AM CST
Transgenomic, Inc. (OTCBB:TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, today announced that it has entered into an agreement with affiliates of Third Security, LLC ("Third Security"
, a leading life sciences investment firm founded by R.J. Kirk, to sell to them 1,443,297 million Series B convertible preferred shares at a price of $4.85 per share for gross proceeds of $7.0 million.
TBIO: 2.60 (-0.02)
Barrick Announces Agreement to Divest its Minority Interest in Marigold in Nevada
Marketwire - Tue Feb 04, 12:11AM CST
All amounts expressed in US dollars unless otherwise indicated.
ABT: 43.37 (-0.32), ABX.TO: 13.79 (+0.82), ABX: 12.16 (+0.82), TBIO: 2.60 (-0.02), DGX: 61.69 (-1.07), SSRI: 5.20 (+0.88), PKI: 43.81 (-0.85)
OTC Daily Alert Stock Watch - Transgenomic, Inc. (OTCQB: TBIO)
WorldStockWire - Thu Sep 05, 4:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
TBIO: 2.60 (-0.02)
TBIO Transgenomic Inc Recent Headline News
Transgenomic Announces Executive Changes
Business Wire - Wed Nov 05, 7:30AM CST
Transgenomic, Inc. (NASDAQ:TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical and research services, today announced certain executive management changes. Mark Colonnese, the Chief Financial Officer and Executive Vice President of Transgenomic, resigned from the Company effective October 30, 2014. Paul Kinnon, Transgenomic's President and Chief Executive Officer, will assume the role of Interim Chief Financial Officer. Additionally, Leon Richards, Transgenomic's Corporate Controller, will take on additional responsibilities as Chief Accounting Officer for Transgenomic.
TBIO: 2.60 (-0.02)
Transgenomic Reports Third Quarter 2014 Financial Results
Business Wire - Thu Oct 30, 6:02AM CDT
Transgenomic, Inc. (NASDAQ:TBIO) today reported financial results for the third quarter ended September 30, 2014, and provided a business update.
TBIO: 2.60 (-0.02)
Transgenomic and University of Melbourne Collaborate to Further Validate Ability of Multiplexed ICE COLD-PCR(TM) to Enable Personalized Cancer Treatment
Business Wire - Thu Oct 30, 6:00AM CDT
--MX-ICP Technology Enables Ultra-Sensitive Detection and Monitoring of Multiple Known and Unknown Cancer Mutations in a Single Assay Using Tumor Biopsy or Blood
TBIO: 2.60 (-0.02)
Transgenomic to Hold Third Quarter Financial Results Conference Call on October 30, 2014 at 8:30AM ET
Business Wire - Thu Oct 23, 6:00AM CDT
Transgenomic, Inc. (NASDAQ: TBIO), today announced that the company will hold its Third Quarter 2014 Financial Results and Business Update Conference Call on Thursday, October 30, 2014 at 8:30 AM ET.
TBIO: 2.60 (-0.02)
Transgenomic Announces $2.375 Million Private Placement Financing
Business Wire - Wed Oct 22, 3:06PM CDT
Transgenomic, Inc. (NASDAQ: TBIO) announced today that it has raised gross proceeds of approximately $2.375 million in a private placement financing with a syndicate of new and existing institutional and other accredited investors. The Company's common shares were priced at $3.25 per share, which represents a premium to the closing stock price on October 21, 2014. For each share of common stock purchased, investors also received a warrant to purchase 0.5 shares of the Company's common stock at an exercise price of $4.00 per share. The warrants have a term of exercise equal to five years from the first date of exercise, which is six months following the closing date. In the aggregate, the Company issued approximately 0.73 million shares of common stock and 0.37 million warrants.
TBIO: 2.60 (-0.02)
Transgenomic to Present at BTIG Emerging Technologies in Healthcare Diagnostics Conference
Business Wire - Wed Sep 24, 6:00AM CDT
Transgenomic, Inc. (NASDAQ:TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical and research services, today announced that senior management will participate in the BTIG Emerging Technologies in Healthcare Diagnostics conference. Transgenomic's Executive Vice President and Chief Financial Officer Mark Colonnese will discuss Personalized Medicine in the CLIA Lab on Monday, September 29, 2014 at 4:10 pm ET.
TBIO: 2.60 (-0.02)
Transgenomic to Present at Fifth Annual Craig-Hallum Alpha Select Conference
Business Wire - Mon Sep 15, 10:00AM CDT
Transgenomic, Inc. (NASDAQ: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical and research services, today announced that senior management will give a corporate presentation at the Fifth Annual Craig-Hallum Alpha Select Conference being held at the Convene Conference Center in New York City. Transgenomic's Executive Vice President and Chief Financial Officer Mark Colonnese will present on Thursday, September 18,2014 at 8:40 am ET.
TBIO: 2.60 (-0.02)
Transgenomic to Present at Rodman & Renshaw 16th Annual Global Investment Conference
Business Wire - Fri Sep 05, 6:00AM CDT
Transgenomic, Inc. (NASDAQ:TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical and research services, today announced that senior management will give a corporate presentation at the Rodman & Renshaw 16th Annual Global Investment Conference being held at the New York Palace Hotel in New York City. Transgenomic will present on Wednesday, September 10, 2014 at 11:15 am ET. Transgenomic Chief Executive Officer Paul Kinnon and Chief Financial Officer Mark Colonnese will participate.
TBIO: 2.60 (-0.02)
Transgenomic Reports Second Quarter 2014 Financial Results
Business Wire - Wed Aug 06, 3:06PM CDT
Transgenomic, Inc. (NASDAQ:TBIO) today reported financial results for the second quarter ended June 30, 2014, and provided a business update.
TBIO: 2.60 (-0.02)
Reminder: Transgenomic to Hold Second Quarter Financial Results Conference Call Today
Business Wire - Wed Aug 06, 6:00AM CDT
Transgenomic, Inc. (NASDAQ: TBIO) today announced the following Webcast:
TBIO: 2.60 (-0.02)
Transgenomic Announces Issuance of New European Patent Covering COLD-PCR Technologies
Business Wire - Thu Jul 31, 6:00AM CDT
Transgenomic, Inc. (NASDAQ: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical and research services, today announced that the European Patent Office has issued a new patent, European Patent No. 21833798, covering one of its COLD-PCR family of DNA amplification technologies. The patent covers Full COLD-PCR, a foundation for the company's highly sensitive ICE COLD-PCR technology. The COLD-PCR technology is owned by the Dana-Farber Cancer Institute, Boston USA, and exclusively licensed to Transgenomic.
TBIO: 2.60 (-0.02)
Transgenomic to Hold Second Quarter Financial Results Conference Call on August 6, 2014
Business Wire - Wed Jul 30, 3:30PM CDT
Transgenomic, Inc. (NASDAQ:TBIO) today announced the following Webcast:
TBIO: 2.60 (-0.02)
Transgenomic Sells Rights to SURVEYOR Mutation Detection Technology and Assets to Integrated DNA Technologies, Inc.
Business Wire - Wed Jul 02, 6:00AM CDT
Transgenomic, Inc. (NASDAQ:TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical and research services, today announced that it has entered into an agreement to sell to Integrated DNA Technologies, Inc. (IDT) the rights to Transgenomic's SURVEYOR Nuclease technology and assets for a minimum of $4.25 million. SURVEYOR Mutation Detection Kits provide researchers with a simple, robust and versatile method to detect mutations and polymorphisms in DNA from a variety of organisms.
TBIO: 2.60 (-0.02)
Dr. Michael A. Luther Joins Transgenomic's Board of Directors
Business Wire - Wed Mar 19, 6:00AM CDT
Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, today announced the appointment of Michael A. Luther, Ph.D., to its Board of Directors. Dr. Luther will also become a member of the Board's audit committee. His appointment became effective March 13, 2014.
TBIO: 2.60 (-0.02)
Transgenomic Reports Fourth Quarter and Fiscal Year 2013 Financial Results
Business Wire - Wed Mar 12, 3:10PM CDT
Transgenomic, Inc. (OTC/BB: TBIO) today reported financial results for the fourth quarter and year ended December 31, 2013, and provided a business update.
TBIO: 2.60 (-0.02)
Reminder: Transgenomic to Hold Fourth Quarter Financial Results Conference Call Today
Business Wire - Wed Mar 12, 7:44AM CDT
Transgenomic, Inc. (OTC/BB: TBIO) today announced the following Webcast:
TBIO: 2.60 (-0.02)
Transgenomic to Hold Fourth Quarter Financial Results Conference Call on March 12, 2014
Business Wire - Thu Mar 06, 10:51AM CST
Transgenomic, Inc. (OTC/BB: TBIO) today announced the following Webcast:
TBIO: 2.60 (-0.02)
Transgenomic Announces $7 Million Convertible Preferred Stock Financing
Business Wire - Thu Mar 06, 6:30AM CST
Transgenomic, Inc. (OTCBB:TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, today announced that it has entered into an agreement with affiliates of Third Security, LLC ("Third Security"
, a leading life sciences investment firm founded by R.J. Kirk, to sell to them 1,443,297 million Series B convertible preferred shares at a price of $4.85 per share for gross proceeds of $7.0 million. TBIO: 2.60 (-0.02)
Barrick Announces Agreement to Divest its Minority Interest in Marigold in Nevada
Marketwire - Tue Feb 04, 12:11AM CST
All amounts expressed in US dollars unless otherwise indicated.
ABT: 43.37 (-0.32), ABX.TO: 13.79 (+0.82), ABX: 12.16 (+0.82), TBIO: 2.60 (-0.02), DGX: 61.69 (-1.07), SSRI: 5.20 (+0.88), PKI: 43.81 (-0.85)
OTC Daily Alert Stock Watch - Transgenomic, Inc. (OTCQB: TBIO)
WorldStockWire - Thu Sep 05, 4:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
TBIO: 2.60 (-0.02)
